Excelsior Medical Co., Ltd. (4104.TW)
TWD 84.9
(6.26%)
TWD 84.9
(6.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.17 Billion TWD | 31.04% |
| 2022 | -1.69 Billion TWD | 26.47% |
| 2021 | -2.3 Billion TWD | -21.22% |
| 2020 | -1.9 Billion TWD | -40.14% |
| 2019 | -1.35 Billion TWD | 31.6% |
| 2018 | -1.98 Billion TWD | -98.59% |
| 2017 | -1 Billion TWD | 39.28% |
| 2016 | -1.64 Billion TWD | -12.38% |
| 2015 | -1.46 Billion TWD | -443.74% |
| 2014 | -269.8 Million TWD | -496.99% |
| 2013 | 67.96 Million TWD | -0.93% |
| 2012 | 68.6 Million TWD | -87.3% |
| 2011 | 540.31 Million TWD | 145.37% |
| 2010 | -1.19 Billion TWD | -56.99% |
| 2009 | -758.6 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.84 Billion TWD | -57.12% |
| 2024 Q2 | -1 Billion TWD | 45.33% |
| 2023 Q4 | -1.17 Billion TWD | 5.05% |
| 2023 FY | -1.17 Billion TWD | 31.04% |
| 2023 Q1 | -1.52 Billion TWD | 10.49% |
| 2023 Q2 | -1.61 Billion TWD | -5.94% |
| 2023 Q3 | -1.23 Billion TWD | 23.41% |
| 2022 Q4 | -1.69 Billion TWD | 3.48% |
| 2022 FY | -1.69 Billion TWD | 26.47% |
| 2022 Q2 | -2.02 Billion TWD | 20.69% |
| 2022 Q1 | -2.55 Billion TWD | -10.66% |
| 2022 Q3 | -1.75 Billion TWD | 13.21% |
| 2021 FY | -2.3 Billion TWD | -21.22% |
| 2021 Q3 | -1.99 Billion TWD | 7.4% |
| 2021 Q4 | -2.3 Billion TWD | -15.74% |
| 2021 Q1 | -2.02 Billion TWD | -6.36% |
| 2021 Q2 | -2.15 Billion TWD | -6.35% |
| 2020 Q3 | -1.58 Billion TWD | 27.45% |
| 2020 Q4 | -1.9 Billion TWD | -19.88% |
| 2020 FY | -1.9 Billion TWD | -40.14% |
| 2020 Q2 | -2.19 Billion TWD | -33.07% |
| 2020 Q1 | -1.64 Billion TWD | -21.08% |
| 2019 Q3 | -697.32 Million TWD | 62.4% |
| 2019 Q2 | -1.85 Billion TWD | -7.25% |
| 2019 Q1 | -1.72 Billion TWD | 13.02% |
| 2019 Q4 | -1.35 Billion TWD | -94.99% |
| 2019 FY | -1.35 Billion TWD | 31.6% |
| 2018 Q2 | -1 Billion TWD | 28.07% |
| 2018 Q4 | -1.98 Billion TWD | -437.43% |
| 2018 FY | -1.98 Billion TWD | -98.59% |
| 2018 Q1 | -1.4 Billion TWD | -39.96% |
| 2018 Q3 | -369.88 Million TWD | 63.29% |
| 2017 Q3 | -733.71 Million TWD | 30.99% |
| 2017 FY | -1 Billion TWD | 39.28% |
| 2017 Q4 | -1 Billion TWD | -36.42% |
| 2017 Q2 | -1.06 Billion TWD | -37.06% |
| 2017 Q1 | -775.75 Million TWD | 52.94% |
| 2016 Q2 | -1.11 Billion TWD | 30.22% |
| 2016 Q1 | -1.6 Billion TWD | -9.11% |
| 2016 FY | -1.64 Billion TWD | -12.38% |
| 2016 Q4 | -1.64 Billion TWD | -51.72% |
| 2016 Q3 | -1.08 Billion TWD | 2.72% |
| 2015 FY | -1.46 Billion TWD | -443.74% |
| 2015 Q1 | -355.09 Million TWD | -31.61% |
| 2015 Q4 | -1.46 Billion TWD | -125.97% |
| 2015 Q2 | -521.39 Million TWD | -46.83% |
| 2015 Q3 | -649.2 Million TWD | -24.51% |
| 2014 FY | -269.8 Million TWD | -496.99% |
| 2014 Q2 | 71.61 Million TWD | 287.67% |
| 2014 Q3 | 165.89 Million TWD | 131.66% |
| 2014 Q4 | -269.8 Million TWD | -262.64% |
| 2014 Q1 | 18.47 Million TWD | -72.82% |
| 2013 Q3 | 825.13 Million TWD | -7.19% |
| 2013 Q4 | 67.96 Million TWD | -91.76% |
| 2013 FY | 67.96 Million TWD | -0.93% |
| 2013 Q2 | 889.01 Million TWD | 2867.54% |
| 2013 Q1 | -32.12 Million TWD | -146.83% |
| 2012 Q1 | 866.64 Million TWD | 60.39% |
| 2012 FY | 68.6 Million TWD | -87.3% |
| 2012 Q4 | 68.6 Million TWD | -57.05% |
| 2012 Q3 | 159.73 Million TWD | -61.61% |
| 2012 Q2 | 416.07 Million TWD | -51.99% |
| 2011 Q3 | -131.83 Million TWD | 64.4% |
| 2011 Q1 | -399.51 Million TWD | 66.45% |
| 2011 Q2 | -370.35 Million TWD | 7.3% |
| 2011 Q4 | 540.31 Million TWD | 509.85% |
| 2011 FY | 540.31 Million TWD | 145.37% |
| 2010 Q4 | -1.19 Billion TWD | 0.0% |
| 2010 FY | -1.19 Billion TWD | -56.99% |
| 2009 FY | -758.6 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Medical Corp. | -283.82 Million TWD | -312.683% |
| OK Biotech Co., Ltd. | 9.94 Million TWD | 11881.402% |
| Applied BioCode Corporation | -378.76 Million TWD | -209.245% |